Biomaterial Database

Clinical experience with cefotaxime in the treatment of serious bone and joint infections. 1982

J L LeFrock, and B B Carr

Cefotaxime, a new parenteral cephalosporin that is beta-lactamase resistant, was evaluated for safety and efficacy in 55 patients (at 22 hospitals) with serious bone and joint infections. Septic arthritis and bursitis and acute and chronic osteomyelitis were treated with 2-16 g of parenteral cefotaxime per day (mean, 7.45 g) for 4-54 days (mean, 22.8 days). Thirty-seven patients had underlying diseases or conditions, 13 patients had infections that were hospital acquired, and 39 patients required surgery. Staphylococcus was the most frequently isolated pathogen. Overall, 39 of the 51 patients who met all criteria for evaluation had satisfactory responses to cefotaxime. The drug was well tolerated by all patients. Further investigation of cefotaxime for the treatment of bone and joint infections is warranted.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008826	Microbial Sensitivity Tests	Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).	Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010019	Osteomyelitis	INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.	Osteomyelitides
D002062	Bursitis	Inflammation or irritation of a SYNOVIAL BURSA, the fibrous sac that acts as a cushion between moving structures of bones, muscles, tendons or skin.	Adhesive Capsulitis,Capsulitis, Adhesive,Frozen Shoulder,Pes Anserine Bursitis,Adhesive Capsulitis of the Shoulder,Capsulitis,Shoulder Adhesive Capsulitis,Adhesive Capsulitides,Adhesive Capsulitides, Shoulder,Adhesive Capsulitis, Shoulder,Bursitides,Bursitides, Pes Anserine,Bursitis, Pes Anserine,Capsulitides,Capsulitides, Adhesive,Capsulitides, Shoulder Adhesive,Capsulitis, Shoulder Adhesive,Frozen Shoulders,Pes Anserine Bursitides,Shoulder Adhesive Capsulitides,Shoulder, Frozen
D002439	Cefotaxime	Semisynthetic broad-spectrum cephalosporin.	Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208	Acute Disease	Disease having a short and relatively severe course.	Acute Diseases,Disease, Acute,Diseases, Acute